Predictors of response to tofacitinib or etanercept in a phase 3 randomized, noninferiority study in patients with moderate to severe chronic plaque psoriasis

被引：0
|
作者：
Lambert, Jo [1 ]
Strohal, Robert [2 ]
de la Cruz, Claudia [3 ]
Thaci, Diamant [4 ]
Bachelez, Herve [5 ]
Iversen, Lars [6 ]
Rottinghaus, Scott [7 ]
Tallman, Anna [8 ]
Tan, Huaming [7 ]
Berstein, Gabriel [9 ]
机构：
[1] Ghent Univ Hosp, Ghent, Belgium
[2] Fed Acad Teaching Hosp Feldkirch, Feldkirch, Austria
[3] Clin Dermacross, Santiago, Chile
[4] Univ Med Sch, Comprehens Ctr Inflammat Med, Schleswig Holstein Campus, Lubeck, Germany
[5] Univ Paris Diderot, Sorbonne Paris Cite, Hop St Louis, AP HP, Paris, France
[6] Aarhus Univ Hosp, Aarhus C, Denmark
[7] Pfizer Inc, Groton, CT USA
[8] Pfizer Inc, New York, NY USA
[9] Pfizer Inc, Cambridge, MA USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2016年 / 74卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
3386
引用
收藏
页码：AB263 / AB263
页数：1
相关论文
共 50 条
  • [41] Association between serum interleukin-17A and clinical response to tofacitinib and etanercept in moderate to severe psoriasis
    Fitz, L.
    Zhang, W.
    Soderstrom, C.
    Fraser, S.
    Lee, J.
    Quazi, A.
    Wolk, R.
    Mebus, C. A.
    Valdez, H.
    Berstein, G.
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2018, 43 (07) : 790 - 797
  • [42] Serum IL-17A at baseline correlates with clinical response to tofacitinib and etanercept in moderate to severe psoriasis
    Berstein, G.
    Zhang, W.
    Soderstrom, C.
    Fraser, S.
    Lee, J.
    Quazi, A.
    Wolk, R.
    Mebus, C.
    Valdez, H.
    Fitz, L.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S33 - S33
  • [43] Characterization of etanercept pharmacokinetics, immunogenicity, and efficacy in pediatric patients with moderate to severe plaque psoriasis
    Langley, Richard G.
    Kasichayanula, Sree
    Trivedi, Mona
    Aras, Gary
    Kaliyaperumal, Arunan
    Yuraszeck, Theresa
    Gibbs, Megan
    Kricorian, Greg
    Paller, Amy S.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB67 - AB67
  • [44] Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis
    Strober, B. E.
    Crowley, J. J.
    Yamauchi, P. S.
    Olds, M.
    Williams, D. A.
    BRITISH JOURNAL OF DERMATOLOGY, 2011, 165 (03) : 661 - 668
  • [45] A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis
    Gottlieb, A. B.
    Langley, R. G.
    Strober, B. E.
    Papp, K. A.
    Klekotka, P.
    Creamer, K.
    Thompson, E. H. Z.
    Hooper, M.
    Kricorian, G.
    BRITISH JOURNAL OF DERMATOLOGY, 2012, 167 (03) : 649 - 657
  • [46] Early clinical response as a predictor of subsequent response to tofacitinib treatment: Results from two phase 3 studies of subjects with moderate to severe plaque psoriasis
    Tan, Huaming
    Valdez, Hernan
    Wolk, Robert
    Tallman, Anna
    Gordon, Kenneth B.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB244 - AB244
  • [47] Early clinical response to tofacitinib treatment as a predictor of subsequent efficacy: Results from two phase 3 studies of patients with moderate-to-severe plaque psoriasis
    Tan, Huaming
    Valdez, Hernan
    Griffiths, Chris E. M.
    Mrowietz, Ulrich
    Tallman, Anna
    Wolk, Robert
    Gordon, Kenneth
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2017, 28 (01) : 3 - 7
  • [48] Two phase 3 studies of oral tofacitinib in patients with moderate to severe plaque psoriasis: 16-week efficacy and safety results
    Papp, Kim A.
    Menter, Martin A.
    Abe, Masatoshi
    Elewski, Boni E.
    Feldman, Steven R.
    Gottlieb, Alice G.
    Thaci, Diamant
    Luger, Thomas
    Tatulych, Svitlana
    Gupta, Pankaj
    Proulx, James
    Lan, Shu-Ping
    Wolk, Robert
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB66 - AB66
  • [49] Efalizumab for patients with moderate to severe plaque psoriasis - A randomized controlled trial
    Gordon, KB
    Papp, KA
    Hamilton, TK
    Walicke, PA
    Dummer, W
    Li, N
    Bresnahan, BW
    Menter, A
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (23): : 3073 - 3080
  • [50] Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: A phase IIIb, randomized, controlled trial
    Papp, KA
    Bressinck, R
    Fretzin, S
    Goffe, B
    Kempers, S
    Gordon, KB
    Caro, I
    Walicke, PA
    Wang, XL
    Menter, A
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2006, 45 (05) : 605 - 614
12345